LATEST ARTICLES

Trifluridine/tipiracil Significantly Improved Overall Survival versus Placebo in Gastric Cancer

The safety and efficacy of trifluridine/tipiracil (Lonsurf®; Taiho Oncology/Taiho Pharmaceutical and Servier) in patients who had undergone gastrectomy, the surgical removal of a part or the whole of the...

FDA Accepts sBLA for Atezolizumab + Abraxane and Carboplatin for Metastatic Non-squamous NSCLC

The United States Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for atezolizumab (Tecentriq®; Roche/Genentech) in combination with albumin-bound paclitaxel or nab-paclitaxel (Abraxane®; Abraxis...

Neoleukin-2/15 – A Novel Immunotherapy Agent Designed to Avoid Common Side Effects

Scientists at the University of Washington Medicine's Institute for Protein Design (IPD) in Seattle, Washington, have created a new protein that mimics the action of a key immune regulatory...

Comparison of State-by-State Data Shows Melanoma Survival Varies Regionally

Cancer of the skin is by far the most common of all cancers and while melanoma accounts for only about 1% of all skin cancers, it causes a large...

Study Confirms Complication Rates and Costs for Drugs and Diagnostics Higher in Lung Cancer

According to a new study from The University of Texas MD Anderson Cancer Center, complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the...

Bristol-Myers Squibb and Celgene Merge

Bristol-Myers Squibb Company (headquartered in New York, New York) and Celgene Corporation (headquartered in Summit, New Jersey) have entered into a definitive merger agreement under which Bristol-Myers Squibb will...